GlassScriptPhysician profile
Marlon Medina
NPI 1306482658
$5,696.89
in general payments reported to CMS, 2019-2025
22 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $568 · 2022: $970 · 2023: $1,434 · 2024: $1,190 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,158.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,997.93 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $766.01 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $675.67 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $326.51 | 2022-2025 | Auvelity |
| Lundbeck LLC | $304.55 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $286.63 | 2021-2025 | Trintellix |
| Corium, LLC | $279.12 | 2022-2025 | Azstarys, Adlarity |
| Ironshore Pharmaceuticals INC. | $154.79 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $143.52 | 2022-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $106.57 | 2023-2024 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $96.42 | 2021-2022 | |
| Tris Pharma INC | $84.62 | 2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $66.79 | 2025 | Jornay Pm |
| Eisai INC. | $66.41 | 2024 | |
| Neurocrine Biosciences, INC. | $62.12 | 2021-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $61.24 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $55.29 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $52.87 | 2022-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $47.78 | 2024 | Spravato |
| Bausch Health US, LLC | $34.32 | 2022-2023 | Aplenzin |
| Adlon Therapeutics L.P. | $14.02 | 2021 | |
| Neos Therapeutics, LP | $13.71 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlon Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.